These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 29731633)

  • 1. Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL study.
    Li H; Li Y; Feng Y; Zhuo J; Turkoz I; Mathews M; Tan W
    Neuropsychiatr Dis Treat; 2018; 14():1107-1117. PubMed ID: 29731633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study.
    Li H; Turkoz I; Zhang F
    Neuropsychiatr Dis Treat; 2016; 12():15-24. PubMed ID: 26730193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, placebo-controlled, double-blind study assessing the efficacy and safety of paliperidone palmitate in Asian patients with schizophrenia.
    Takahashi N; Takahashi M; Saito T; Iizumi M; Saito Y; Shimizu H; Matsumura T
    Neuropsychiatr Dis Treat; 2013; 9():1889-98. PubMed ID: 24353421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study.
    Savitz AJ; Xu H; Gopal S; Nuamah I; Ravenstijn P; Hough D; Mathews M; Feng Y; Yu L; Takahashi M; Liu D; Wang G; Yoon JS; Chen JJ
    Neuropsychiatr Dis Treat; 2017; 13():2193-2207. PubMed ID: 28860777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of aripiprazole lauroxil in patients with acute schizophrenia as assessed by the Positive and Negative Syndrome Scale-supportive analyses from a Phase 3 study.
    Citrome L; Risinger R; Cutler AJ; Du Y; Zummo J; Nasrallah HA; Silverman BL
    CNS Spectr; 2018 Aug; 23(4):284-290. PubMed ID: 28625204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Post-hoc comparison of paliperidone palmitate to oral risperidone during initiation of long-acting risperidone injection in patients with acute schizophrenia.
    Gopal S; Pandina G; Lane R; Nuamah I; Remmerie B; Coppola D; Hough D
    Innov Clin Neurosci; 2011 Aug; 8(8):26-33. PubMed ID: 21922067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophrenia: an open-label, single-arm, prospective, interventional study.
    Si T; Zhang K; Tang J; Fang M; Li K; Zhuo J; Feng Y
    Neuropsychiatr Dis Treat; 2015; 11():1483-92. PubMed ID: 26150719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of acute schizophrenia with paliperidone ER: predictors for treatment response and benzodiazepine use.
    Heres S; Don L; Herceg M; Bidzan L; Blanc M; Siracusano A; Maciulis V; Lahaye M; Schreiner A
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():207-12. PubMed ID: 24096139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia.
    Hargarter L; Bergmans P; Cherubin P; Keim S; Conca A; Serrano-Blanco A; Bitter I; Bilanakis N; Schreiner A
    Expert Opin Pharmacother; 2016 Jun; 17(8):1043-53. PubMed ID: 27042990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study.
    Zhao J; Li L; Shi J; Li Y; Xu X; Li K; Zhang L; Cai S; Feng Y; Zhuo J; Liu W; Lu H
    Neuropsychiatr Dis Treat; 2017; 13():2045-2056. PubMed ID: 28814873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-monthly injection of paliperidone palmitate in patients with recently diagnosed and chronic schizophrenia: a post-hoc comparison of efficacy and safety.
    Si T; Zhuo J; Turkoz I; Mathews M; Tan W; Feng Y
    Expert Opin Pharmacother; 2017 Dec; 18(17):1799-1809. PubMed ID: 29141463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia.
    Nasrallah HA; Gopal S; Gassmann-Mayer C; Quiroz JA; Lim P; Eerdekens M; Yuen E; Hough D
    Neuropsychopharmacology; 2010 Sep; 35(10):2072-82. PubMed ID: 20555312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics.
    Alphs L; Bossie CA; Sliwa JK; Fu DJ; Ma YW; Hulihan J
    Neuropsychiatr Dis Treat; 2013; 9():341-50. PubMed ID: 23493643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paliperidone extended release: a review of its use in the management of schizophrenia.
    Chwieduk CM; Keating GM
    Drugs; 2010 Jul; 70(10):1295-317. PubMed ID: 20568835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial.
    Alphs L; Bossie CA; Sliwa JK; Ma YW; Turner N
    Ann Gen Psychiatry; 2011 Apr; 10(1):12. PubMed ID: 21481243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aripiprazole Once-Monthly in the Treatment of Acute Psychotic Episodes in Schizophrenia: Post Hoc Analysis of Positive and Negative Syndrome Scale Marder Factor Scores.
    Ismail Z; Peters-Strickland T; Miguelez M; Baker RA; Hertel P; Eramo A; Jin N; Perry P; Sanchez R; McQuade RD; Kane JM
    J Clin Psychopharmacol; 2017 Jun; 37(3):347-350. PubMed ID: 28383362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.
    Schreiner A; Caspi A; Bergmans P; Cherubin P; Keim S; Lara E; Pinchuk I; Schuepbach D; Suleman S; Hargarter L
    Psychopharmacology (Berl); 2017 Jan; 234(1):3-13. PubMed ID: 27815602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of long-acting paliperidone palmitate once-monthly on negative and depressive symptoms in patients with schizophrenia switched from previous unsuccessful treatment with oral aripiprazole.
    Schreiner A; Bergmans P; Cherubin P; Hargarter L
    Ther Adv Psychopharmacol; 2017 Feb; 7(2):59-65. PubMed ID: 28255435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia.
    Zhang F; Si T; Chiou CF; Harris AW; Kim CY; Jahagirdar P; Ascher S
    Neuropsychiatr Dis Treat; 2015; 11():657-68. PubMed ID: 25792835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching to paliperidone extended release in patients with schizophrenia dissatisfied with previous olanzapine treatment: Post hoc analysis of an open-label, prospective study.
    Si TM; Cai SL; Zhuo JM; Zhang LL
    Medicine (Baltimore); 2019 Jan; 98(3):e13688. PubMed ID: 30653088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.